Literature DB >> 21355841

Texaphyrins: tumor localizing redox active expanded porphyrins.

Jonathan F Arambula1, Christian Preihs, Derric Borthwick, Darren Magda, Jonathan L Sessler.   

Abstract

Texaphyrins, a class of tumor selective expanded porphyrins capable of coordinating large metals, have been found to act as redox mediators within biological systems. This review summarizes studies involving their experimental use in cancer chemotherapy. Mechanistic insights involving their presumed mode of action are also described, as well as certain structure activity relationships. Finally, newer texaphyrin-based applications associated with targeted drug delivery are presented.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21355841      PMCID： PMC3224805          DOI： 10.2174/187152011795255894

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN： 1871-5206            Impact factor:   2.505


  103 in total

1.  Functional mimics of superoxide dismutase enzymes as therapeutic agents.

Authors:  D P Riley
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

Review 2.  Introduction to metallothionein.

Authors:  B L Vallee
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Redox active disulfides: the thioredoxin system as a drug target.

Authors:  D L Kirkpatrick; G Ehrmantraut; S Stettner; M Kunkel; G Powis
Journal:  Oncol Res       Date:  1997       Impact factor: 5.574

4.  Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation.

Authors:  S J Wei; A Botero; K Hirota; C M Bradbury; S Markovina; A Laszlo; D R Spitz; P C Goswami; J Yodoi; D Gius
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

5.  Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas.

Authors:  Joon Hyuk Choi; Tae Nyeun Kim; Seongyong Kim; Suk-Hwan Baek; Jung Hye Kim; Seung Rock Lee; Jae-Ryong Kim
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

6.  Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.

Authors:  Shanta Dhar; Weston L Daniel; David A Giljohann; Chad A Mirkin; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2009-10-21       Impact factor: 15.419

7.  Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.

Authors:  Seyed Isaac Hashemy; Johanna S Ungerstedt; Farnaz Zahedi Avval; Arne Holmgren
Journal:  J Biol Chem       Date:  2006-02-14       Impact factor: 5.157

8.  Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species.

Authors:  Darren Magda; Nikolay Gerasimchuk; Philip Lecane; Richard A Miller; John E Biaglow; Jonathan L Sessler
Journal:  Chem Commun (Camb)       Date:  2002-11-21       Impact factor: 6.222

9.  Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice.

Authors:  Susan E Browne; L Jackson Roberts; Phyllis A Dennery; Susan R Doctrow; M Flint Beal; Carrolee Barlow; Rodney L Levine
Journal:  Free Radic Biol Med       Date:  2004-04-01       Impact factor: 7.376

10.  The role of oxoammonium cation in the SOD-mimic activity of cyclic nitroxides.

Authors:  Sara Goldstein; Gabor Merenyi; Angelo Russo; Amram Samuni
Journal:  J Am Chem Soc       Date:  2003-01-22       Impact factor: 15.419
View more
  12 in total

Review 1.  A combination of two antioxidants (an SOD mimic and ascorbate) produces a pro-oxidative effect forcing Escherichia coli to adapt via induction of oxyR regulon.

Authors:  Ines Batinic-Haberle; Zrinka Rajic; Ludmil Benov
Journal:  Anticancer Agents Med Chem       Date:  2011-05-01       Impact factor: 2.505

Review 2.  Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics.

Authors:  Ines Batinic-Haberle; Zrinka Rajic; Artak Tovmasyan; Julio S Reboucas; Xiaodong Ye; Kam W Leong; Mark W Dewhirst; Zeljko Vujaskovic; Ludmil Benov; Ivan Spasojevic
Journal:  Free Radic Biol Med       Date:  2011-05-06       Impact factor: 7.376

Review 3.  Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Authors:  D Lynn Kirkpatrick; Garth Powis
Journal:  Antioxid Redox Signal       Date:  2016-04-22       Impact factor: 8.401

4.  Porphyrinoid Drug Conjugates.

Authors:  Jonathan F Arambula; Jonathan L Sessler
Journal:  Chem       Date:  2020-07-09       Impact factor: 22.804

5.  Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors.

Authors:  Stephen T Keir; Mark W Dewhirst; John P Kirkpatrick; Darell D Bigner; Ines Batinic-Haberle
Journal:  Anticancer Agents Med Chem       Date:  2011-02       Impact factor: 2.505

6.  Detailed structural and spectroscopic elucidation of ferrocenium coupled N-heterocyclic carbene gold(I) complexes.

Authors:  Garrett L Reinhard; Selvakumar Jayaraman; Joshua W Prybil; Jonathan F Arambula; Kuppuswamy Arumugam
Journal:  Dalton Trans       Date:  2022-01-25       Impact factor: 4.569

7.  Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging.

Authors:  Sashiprabha M Vithanarachchi; Matthew J Allen
Journal:  Curr Mol Imaging       Date:  2012-10-01

Review 8.  Recent developments in texaphyrin chemistry and drug discovery.

Authors:  Christian Preihs; Jonathan F Arambula; Darren Magda; Heeyeong Jeong; Dongwon Yoo; Jinwoo Cheon; Zahid H Siddik; Jonathan L Sessler
Journal:  Inorg Chem       Date:  2013-04-04       Impact factor: 5.165

9.  A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells.

Authors:  Jonathan F Arambula; Jonathan L Sessler; Zahid H Siddik
Journal:  Medchemcomm       Date:  2012       Impact factor: 3.597

Review 10.  Design, mechanism of action, bioavailability and therapeutic effects of mn porphyrin-based redox modulators.

Authors:  Artak Tovmasyan; Huaxin Sheng; Tin Weitner; Amanda Arulpragasam; Miaomiao Lu; David S Warner; Zeljko Vujaskovic; Ivan Spasojevic; Ines Batinic-Haberle
Journal:  Med Princ Pract       Date:  2012-10-16       Impact factor: 1.927
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.